Background: Accurate risk assessment of atherosclerotic cardiovascular disease (ASCVD) is essential to effectively balance the risks and benefits of therapy for primary prevention.
F
or more than a decade, national guidelines have recommended the use of an objective tool to assess risk for coronary heart disease (CHD) based on the Framingham risk score (FRS) to guide therapy for primary prevention (1) (2) (3) (4) . The original Framingham risk prediction algorithm to predict CHD (known as FRS-CHD) incorporated age; sex; diabetes; systolic and diastolic blood pressures; levels of total, low-density lipoprotein, and high-density lipoprotein cholesterol; and smoking to estimate a 10-year risk for angina, myocardial infarction, or death due to CHD (4) . In 2001, the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATPIII] ) recommended a modified FRS (ATPIII-FRS-CHD) and set thresholds and goals for lipidlowering therapy based on the 10-year CHD risk (5) .
The applicability of Framingham-based algorithms to modern populations has been questioned (6 -10) . Framingham-based scores are based on a homogeneous, geographically limited, white male-dominated cohort from a prior generation when cardiovascular risk profiles and preventive pharmacotherapy were both less well-developed and used than in modern cohorts. Multiple studies in diverse populations suggest that Framingham-based risk-scoring systems may misclassify risk, particularly in women, and overestimate CHD risk (6, 7, 9, 11) . In response, the Reynolds Risk Score (RRS) was developed in 2007 and included parental history of premature CHD and high-sensitivity Creactive protein (12) . To address concerns that the original Framingham-based scores ignored other increasingly common atherosclerotic cardiovascular disease (ASCVD) events, such as stroke, an FRS for the prediction of CVD (FRS-CVD) was developed in 2008 (11) .
Most recently, the American Heart Association (AHA) and the American College of Cardiology (ACC) developed a new ASCVD risk score to guide ASCVD risk-reducing therapy (13) . This new risk score was derived from 4 racially and geographically diverse prospective cohort studies (independent from MESA [Multi-Ethnic Study of Atherosclerosis]), including "applicable data" from the Framingham Original and Offspring Study cohorts (13) (14) (15) (16) . This new risk score uses the same traditional risk factors as the original FRSs and offers separate equations for white and African American men and women (Appendix Table 1 , available at www.annals.org).
Both the guideline writing committee and several investigator groups found that the AHA-ACC-ASCVD risk score developed in 2013 overestimated risk in independent cohorts (10, 13, 17, 18) . Overestimation is of particular clinical relevance at the 10-year predicted risk threshold of 7.5% given recent guideline recommendations encouraging pharmacotherapy treatment above this risk level (19) . We sought to compare the calibration and discrimination of these risk scores in an age-, sex-, and race-balanced, modern multiethnic population without clinical ASCVD at enrollment. We also sought to understand whether the use of preventive therapies (aspirin, lipid-lowering or antihypertensive therapy, and interim revascularization), common to modern cohorts, was responsible for risk score overestimation. Such information might be useful in helping to guide implementation policy and future risk score and guideline development.
METHODS
MESA is a multicenter prospective communitybased epidemiologic study of cardiovascular disease in an age-and sex-balanced, multiethnic cohort. The study design and methods have been previously published (20). In brief, 6814 participants aged 45 to 84 years who identified themselves as white, African American, Hispanic, or Chinese were recruited from 6 U.S. communities in 2000 to 2002. Participants were free of clinical CVD at enrollment. Medical history, anthropometric measurements, and laboratory data were assessed as previously described (20). Parental history of CHD was considered positive at the baseline visit if either parent had experienced a heart attack. Sensitivity analysis was done using the RRS definition of premature parental history of CHD (mother or father aged <60 years with myocardial infarction) on the subsample reporting detailed family history data at the second MESA visit (92% of participants).
Follow-up and Event Adjudication
New CHD and CVD events were recorded over a median 10.2-year follow-up. Participants were interviewed by telephone every 9 to 12 months to identify interim hospital admissions, outpatient diagnoses of CHD or CVD, and deaths. To verify self-reported diagnoses, copies of medical records for all hospitalizations and outpatient CHD and CVD diagnoses as well as death certificates were requested. Two physician members of the MESA mortality and morbidity review committee independently classified events; the full committee made the final classification for disagreements. Events consisted of myocardial infarction; definite or probable angina; resuscitated cardiac arrest; stroke (not transient ischemic attack); or death due to CHD, stroke, atherosclerosis, or other CVD. A detailed description of the MESA method is available at www.mesa -nhlbi.org.
In an attempt to identify any ASCVD events missed by the MESA study, we examined, at any point during follow-up, all 3175 MESA participants included in the Part A hospital claims within the Centers for Medicare & Medicaid Services (CMS) billing database for cases not adjudicated by MESA.
Risk Score Calculations
Five risk prediction scores were calculated from the baseline MESA data (2000 to 2002): FRS-CHD, FRS-CVD, ATPIII-FRS-CHD, RRS, and AHA-ACC-ASCVD. The study population was limited to participants aged 50 to 74 years to meet the target population for each score (Appendix Table 1 ). Because the ATPIII-FRS-CHD and RRS for men were not developed for risk calculation among people with diabetes, MESA participants with diabetes at the baseline examination (12%) were excluded from these analyses. Additional exclusion of participants with missing data required for risk score calculation (2.7%) resulted in a final sample size of 4227.
Risk scores were calculated with the equationbased method (21) for each model (4, 5, (11) (12) (13) 22 (23, 24) . This formula was evaluated for accuracy in our cohort by calculating HbA 1c levels from fasting glucose levels at the second visit and was found to correlate well with measured HbA 1c levels at this time point (r = 0.80).
Predicted and Observed Number of Events
For each risk score, we reported the number of expected events and the number of observed events specific to the target end point of that score (Appendix Table 1 ). Events were censored at 10-year follow-up. For each participant with fewer than 10 years of followup, including those who died, we lowered their 10-year risk estimate to correspond to their length of follow-up
EDITORS' NOTES Context
Accurate risk prediction is an important component of guidelines about interventions to prevent cardiovascular disease.
Contribution
This study found that 4 prominent risk prediction tools overestimate the risk for cardiovascular disease, and a fifth tool underestimated risk among women. The use of preventive therapies did not seem to be the reason for the overprediction observed.
Implication
The limitations of available risk prediction tools require consideration and improvement to better guide prevention interventions. using an exponential survival function to scale the risk score. If Fr10 denotes the 10-year proportion with events according to an FRS, then the 1-year proportion is: FR1 = Ϫln(1 Ϫ Fr10)/10. So, for a person with 8.5 years of follow-up: FR8.5 = 1 Ϫ exp(ϪFR1 × 8.5). Median follow-up in MESA was 10.2 years; 2692 (62%) and 3766 (89%) participants had 10 and 9 or more years of follow-up, respectively. Hosmer-Lemeshow plots were examined separately for men and women to evaluate how well each model fit the observed CVD events. Further, HosmerLemeshow tests for goodness of fit ranked participants according to their predicted probability of having an event and divided them into 10 groups, each of which was represented by a dot on the calibration plots. An overall chi-square statistic was calculated separately for men and women for each score and outcome.
The cumulative effect of multiple treatments was evaluated by doing a sensitivity analysis that included regular aspirin use, lipid-lowering or antihypertensive medication use, and any coronary revascularization. In an effort to study revascularizations that may have prevented subsequent events, all revascularizations more than 2 days before an event or revascularizations not followed by any event were selected for modeling.
Discrimination
The discriminative capability of each risk score was compared separately for men and women using the c-statistic (25) . The discrimination slope was also calculated as the absolute difference in the average predictions for those with and without the outcome.
Role of the Funding Source
The National Heart, Lung, and Blood Institute had no role in the design, conduct, analysis, or reporting of this study.
RESULTS
Baseline characteristics are described in Table 1 . Participants' mean age was 61.5 years, and 53.5% were women. Approximately 42% were white, 26% were African American, 20% were Hispanic, and 12% were Chinese. Aspirin use, lipid-lowering or antihypertensive therapy at baseline or any time during study follow-up, and revascularizations before an event are shown in Appendix Tables 2 and 3 (available at www.annals.org). Statins were the drugs used for 92.5% to 94% of participants receiving lipid-lowering therapy (Appendix Table 2 ).
The FRS-CHD, FRS-CVD, ATPIII-FRS-CHD, and AHA-ACC-ASCVD overestimated risk for the cardiovascular end points they were designed to predict by 53%, 37%, 154%, and 86%, respectively, in men and 48%, 8%, 46%, and 67%, respectively, in women ( Table 2) . The overall discordance between observed and predicted cardiovascular events was lowest for the RRS (Ϫ3%).
Discordance between observed and expected risk was found throughout the risk continuum, including those at moderate risk ( Figures 1 and 2 and Tables 3  and 4 ). This is evident in the Hosmer-Lemeshow calibration plots, with a predominance of overestimation in 
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men and women by all of the risk scores except the RRS, which showed a predominance of underestimation in women, and the FRS-CVD, which revealed little discordance in women ( Figure 2 and Table 4 ). Participants with an AHA-ACC-ASCVD risk score greater than 7.5% are of particular relevance to the 2013 ACC-AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. In men with an AHA-ACC-ASCVD risk score of 7.5% to 10%, the actual event rate was only 3% ( Table 3) .
Among women with an AHA-ACC-ASCVD risk score of 7.5% to 10%, the actual event rate was only 5.1% ( Table 4 ). An evaluation of discrimination (how well each model discriminated between a participant having or not having an event) revealed little difference between the performance of the risk scores in men (c-statistic, 0.69 to 0.71; discrimination slope, 0.05 to 0.09). Among women, the c-statistic and discrimination slope varied little among the FRS-CVD, ATPIII-FRS-CHD, RRS, and AHA-ACC-ASCVD risk scores (c-statistic, 0.67 to 0.72; discrimination slope, 0.02 to 0.05) but were lower (less able to discriminate if a participant was to have or not have an event) for the FRS-CHD risk score (c-statistic, 0.60; discrimination slope, 0.01) ( Table 2 The effect of medication use at baseline and follow-up and interim revascularizations on the discordance between the observed and expected event rate was evaluated in a sensitivity analysis restricted to men and women who did not receive any preventive therapy (aspirin use, lipid-lowering or antihypertensive medication use, and any coronary revascularization) as assessed at baseline and all 5 follow-up visits. Limiting our evaluation to untreated participants (aspirin or lipid-lowering or antihypertensive medication use at baseline or at any of the 5 follow-up visits or coronary revascularization) resulted in greater risk overestimation for all risk scores examined ( Table 5 ). An analysis that censored participants at the time of cholesterollowering medication use or revascularization also showed greater overestimation by the AHA-ACC-ASCVD risk score (Appendix Table 4 , available at www .annals.org). A sensitivity analysis using the RRS definition of premature parental history of CHD resulted in a change from a 9% overestimation to a 5% underestimation of risk via the RRS in men and greater underestimation (from Ϫ21% to Ϫ27%) via the RRS among women. The ability of the RRS to discriminate between those who did and did not have events (c-statistics) remained unchanged for men but worsened for women (c-statistic increased from 0.72 to 0.70) when the RRS definition of premature parental history of CHD was used (Appendix Table 5 , www.annals.org). Analyses using the calculated HbA 1c level and including participants with diabetes produced only modest changes in our results (Appendix Table 6 , www.annals.org).
A sensitivity analysis of the 3175 MESA participants in the CMS database found 16 ASCVD events not identified as 1 of the 160 MESA-adjudicated ASCVD events (9%). Restricting the analysis to participants included in the CMS database, and including the potential 9% increase in ASCVD events suggested by CMS linkage, we observed greater overestimation by the AHA-ACC-ASCVD risk score for the total cohort, men, and women (Appendix Table 7 , available at www.annals.org) and 
DISCUSSION
This comparative analysis done in a well-characterized; age-, sex-and race-balanced; community-based; multiethnic cohort showed that 3 commonly used cardiovascular risk scores (FRS-CHD, FRS-CVD, and ATPIII-FRS-CHD) and the newly recommended risk score (AHA-ACC-ASCVD) all overestimate the risk for their intended outcome in men by 37% to 154%. The RRS had the best calibration for men with only 9% overestimation. The FRS-CHD, ATPIII-FRS-CHD, and AHA-ACC-ASCVD risk scores also overestimated risk by 46% to 67% in women. The FRS-CVD had the best calibration among women with 8% overestimation, whereas the RRS underestimated risk among women by 21%. Overestimation predominated and was noted throughout the continuum of risk for these tools, including the intermediate risk groups in which treatment decisions balancing therapeutic risk and benefit are more challenging.
A recent study by Muntner and colleagues (18) evaluated a 5-year version of the 10-year AHA-ACC-ASCVD risk score in the REGARDS (REasons for Geographic and Racial Differences in Stroke) cohort at 5-year follow-up. Consistent with our finding, the authors found overestimation of risk and similar discrimination with the AHA-ACC-ASCVD risk score in the REGARDS participants aged 45 to 79 years without a history of CHD, stroke, heart failure (identified exclusively by use of digoxin), or atrial fibrillation at baseline. They found less overestimation in a post hoc subgroup of "clinically relevant" participants and in participants older than 65 years when using a combination of adjudicated and nonadjudicated events identified in the CMS billing database. Limitations of this study include the possible decreased specificity of events identified in CMS without further adjudication and follow-up limited to 5 years to evaluate a 10-year risk score. A recent evaluation of the AHA-ACC-ASCVD, the ATPIII-FRS-CHD, and the European Society of Cardiology risk scores in the Rotterdam study cohort found event overestimation similar to that noted in our study (17) . A 
ORIGINAL RESEARCH Calibration and Discrimination Among CVD Risk Scores
prior analysis by Cook and colleagues compared CVD risk scores using a multiethnic prospective cohort of more than 90 000 postmenopausal women. Consistent with our study, this study showed overestimation of risk with both the ATPIII-FRS-CHD and FRS-CVD but not the RRS (8). However, in both the Rotterdam and Cook and colleagues' studies, evaluations were done in cohorts with limited diversity and did not account for the differences in end points for which each of the risk scores was designed. Our study compares the different risk calculators with their designed end points for each score in a sex-balanced, multiethnic, middle-aged modern cohort.
Estimation of absolute cardiovascular risk is at the core of national guidelines for the appropriate use of cholesterol-lowering medication and aspirin in the primary care setting (19, 26) . Although overestimation of risk with the AHA-ACC-ASCVD risk score was acknowledged in the new risk assessment guidelines and confirmed by others (10, 13, 17, 18 ), our analysis further shows a lack of superior calibration or discrimination compared with older risk scores.
We noted several potential reasons for the systematic overestimation when applying these risk scores to the MESA cohort: changing significance of risk factors between older and modern cohorts, more effective therapy for preventing cardiovascular events despite persistence of risk factors, healthy cohort effect (selection bias at cohort enrollment), and incomplete capture of cardiovascular events.
The first 3 explanations may be summarized by the potentially problematic use of cohorts developed decades ago to derive risk scores designed to be used at the present time. Even the newest risk score, the AHA-ACC-ASCVD score, was developed from cohorts that are decades old (13) (14) (15) (16) 27) .
Changing significance of risk factors between older cohorts that were used to develop these risk scores and the more modern MESA cohort may explain the poor estimation of effect of individual risk factors included in the risk scores. For example, smoking is dichotomized as a "yes" or "no" variable in all risk score models evaluated in this study. However, dose (or number) of cigarettes smoked and content of cigarettes have both changed substantially over time (28, 29) . Unmeasured risk factors that have changed over time, such as salt and trans fat intakes, secondhand smoke exposure, and environmental pollution, may also explain some of the residual overestimation not accounted for in our models. Although 4 of the evaluated risk scores overestimated absolute risk in women, our analysis indicates that women were associated with less overestimation than men in these models.
Risk score overestimation has been hypothesized to be a reflection of modern cardiovascular disease therapy (aspirin, lipid-lowering or antihypertensive medication, and revascularization) resulting in reduction of incident CVD events (30) . Modern therapy may directly reduce CVD events and may also change the quantitative relationship between risk factors and CVD outcomes. In our study, however, these therapiesassessed at the time of risk score calculation and at any of the 5 MESA follow-up visits-were not associated with risk score overestimation in MESA. In fact, overestimation was greater in our analysis limited to participants who were not treated with any of these preventive therapies. This finding may be because participants not treated with these methods have healthy characteristics not captured by the risk scores or, in the case of lipidlowering therapy at baseline, the effect of the medication is accounted for by the cholesterol variables in the prediction models.
The MESA participants did not have known CVD at baseline. Participants who enroll in research studies may be more health-conscious and have better general health practices than those who do not. In this way, MESA may not be an accurate representation of the general population. This limitation is shared by all of the studies used to derive risk score models and is not unique to MESA. The RRS underestimated risk by only 3% in our cohort. Likewise, in a modern study of randomly selected adult participants enrolled between 2000 and 2003 from the metropolitan Ruhr area in Germany, the FRS overestimated risk by more than 2-fold in the 93% of participants without known coronary artery disease at baseline (31) . Further, this new risk score displayed worse calibration (up to 38% overestimation) and discrimination in the "contemporary" years of follow-up of the pooled derivation cohort than the earlier years of follow-up (13) . In sum, this suggests that a unique healthy cohort effect in MESA is unlikely to be solely responsible for risk overestimation.
Epidemiologic methods for ascertainment of clinical events seem to be similar in MESA with those of the studies used to derive all of the risk scores, except for 2 of the 4 cohorts used to derive the AHA-ACC-ASCVD risk score (8, 11, 15, 16, 27, 32) . These 2 cohorts included additional surveillance of ASCVD events (16, 33) . MESA was successful in obtaining medical records 
for approximately 98% of reported hospitalized CHD and CVD events and information on 95% of reported outpatient cardiovascular diagnostic encounters. Followup telephone interviews were completed with 92% of living participants. To further explore the possibility of missed events, we analyzed CMS data. Our analysis suggests that no more than 9% of myocardial infarctions and strokes could have been missed among the MESA participants in our analytic sample. This is a highend estimate; some of the CMS events are falsepositive because of the nature of billing data. Sensitivity analysis using CMS-identified events did not significantly curtail AHA-ACC-ASCVD risk score overestimation in MESA. Accurate cardiac risk estimation is essential to balancing the risks and benefits of preventive therapies. For example, current cholesterol management guidelines recommend consideration of statin therapy for participants with an AHA-ACC-ASCVD risk calculation of 7.5% or more over 10 years (19) . Overestimation of risk would likely result in increased use of preventive medications, potentially exposing some patients to the unnecessary risks of these drugs. In particular, aspirin use in primary prevention is known to be a delicate balance between cardiovascular risk reduction and increased incidence of bleeding. Overestimation of cardiovascular risk may result in aspirin treatment of lowrisk participants who are more likely to be harmed from bleeding than to benefit from a reduction in CVD. Underestimation of risk, which was seen in women with the RRS, would be expected to result in undertreatment with appropriate therapies and more preventable CVD events.
In addition to patient safety, overestimation of risk has implications for public health planning with accompanying financial ramifications for a heavily burdened health care system. Statins, for example, although clearly cost-effective in secondary prevention or highrisk primary prevention patients, become less costeffective as primary prevention for low-risk patients (34, 35) . Overestimation of risk could result in more health care dollars spent, less health gain, and exposure to drug side effects.
The RRS for men and the ATPIII-FRS-CHD risk score were not developed for risk calculation among people with diabetes, so the exclusion of these participants may have limited the effectiveness of the non-RRS and non-ATPIII-FRS-CHD risk scores that included diabetes in their risk score calculation. Sensitivity analysis showed that inclusion of diabetes had inconsistent effect on risk prediction, which resulted in no change in our overall study conclusions.
Our results indicate that 4 of the 5 risk estimation algorithms, including the AHA-ACC-ASCVD risk score, overestimate risk by 37% to 154% in men and 8% to 67% in women. One risk score, the RRS, had superior calibration and equal discrimination compared with the other scores evaluated, but it underestimated risk in women. Medication use and interim revascularizations are not robust explanations of the overestimation.
Accurate estimation of absolute risk underpins the effort by the AHA and ACC to update the prevention guidelines and is required to effectively balance therapeutic risk and benefit of an intervention for an individual patient or entire population. Physicians treating patients similar to those in MESA may consider interpreting the absolute risk generated by the new risk score with caution. 
